+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biocartis Group NV (BCART) - Product Pipeline Analysis, 2020 Update

  • ID: 5240158
  • Company Profile
  • January 2021
  • 80 pages
  • GlobalData
  • Biocartis NV

FEATURED COMPANIES

  • Augurix SA
  • Biotechnostics GmbH
  • Buhlmann Laboratories AG
  • Celyad Oncology
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Biocartis Group NV (Biocartis) operates as a molecular diagnostics company that provides personalized medicine for patients through its molecular diagnostics. The company undertakes the development of diagnostics technology platforms for multiplexed detection of bio-analytes, with oncology as its key focus area. Its Idylla is a molecular diagnostics system that provides easy access to clinical molecular diagnostic information. Biocartis also offers a wide range of oncology assays such as Idylla BRAF Mutation Test, Idylla EGFR Mutation Test, Idylla KRAS Mutation Test, and Idylla NRAS Mutation. The company has operations in Belgium and Switzerland. Biocartis is headquartered in Mechelen, Belgium.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Biocartis Group NV
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Augurix SA
  • Biotechnostics GmbH
  • Buhlmann Laboratories AG
  • Celyad Oncology
Biocartis Group NV Company Overview
  • Biocartis Group NV Company Snapshot
  • Biocartis Group NV Pipeline Products and Ongoing Clinical Trials Overview
  • Biocartis Group NV - Pipeline Analysis Overview
  • Biocartis Group NV - Key Facts
  • Biocartis Group NV - Major Products and Services
  • Biocartis Group NV Pipeline Products by Development Stage
Biocartis Group NV Pipeline Products Overview
  • EGFR Colon Cancer Test
  • EGFR Colon Cancer Test Product Overview
  • Idylla - EGFR/BRAF+ Test
  • Idylla - EGFR/BRAF+ Test Product Overview
  • Idylla - KRAS-NRAS-BRAF Test
  • Idylla - KRAS-NRAS-BRAF Test Product Overview
  • Idylla ABC Assay
  • Idylla ABC Assay Product Overview
  • Idylla Blood Stream Infections Panel
  • Idylla Blood Stream Infections Panel Product Overview
  • Idylla Companion Diagnostic Assay
  • Idylla Companion Diagnostic Assay Product Overview
  • Idylla ctEGFR Assay
  • Idylla ctEGFR Assay Product Overview
  • Idylla Endometrium Assay
  • Idylla Endometrium Assay Product Overview
  • Idylla Endpoint CDx Test
  • Idylla Endpoint CDx Test Product Overview
  • Idylla Extended KRAS Mutation Test
  • Idylla Extended KRAS Mutation Test Product Overview
  • Idylla Extended NRAS Mutation Test
  • Idylla Extended NRAS Mutation Test Product Overview
  • Idylla Gene Fusion Assay
  • Idylla Gene Fusion Assay Product Overview
  • Idylla Hematology Assay
  • Idylla Hematology Assay Product Overview
  • Idylla HPV Test - Head & Neck Cancer
  • Idylla HPV Test - Head & Neck Cancer Product Overview
  • Idylla Immuno Tx Panel Test
  • Idylla Immuno Tx Panel Test Product Overview
  • Idylla KRAS Mutation Test
  • Idylla KRAS Mutation Test Product Overview
  • Idylla Meningitis Assay
  • Idylla Meningitis Assay Product Overview
  • Idylla MERS Assay
  • Idylla MERS Assay Product Overview
  • Idylla MSI CDx
  • Idylla MSI CDx Product Overview
  • Idylla MSI Test
  • Idylla MSI Test Product Overview
  • Idylla Multiplex Respiratory Panel
  • Idylla Multiplex Respiratory Panel Product Overview
  • Idylla Neuro Panel Test
  • Idylla Neuro Panel Test Product Overview
  • Idylla Neurological Disease Assay
  • Idylla Neurological Disease Assay Product Overview
  • Idylla NGS Prep Panel - Lung
  • Idylla NGS Prep Panel - Lung Product Overview
  • Idylla NRAS Mutation Test
  • Idylla NRAS Mutation Test Product Overview
  • Idylla NRAS-BRAF Mutation Test
  • Idylla NRAS-BRAF Mutation Test Product Overview
  • Idylla Oncotype DX Prostate
  • Idylla Oncotype DX Prostate Product Overview
  • Idylla Resistance Monitoring Assay
  • Idylla Resistance Monitoring Assay Product Overview
  • Idylla Retrieve - NGS Hotspot Panel Assay
  • Idylla Retrieve - NGS Hotspot Panel Assay Product Overview
  • Idylla Sepsis Assay
  • Idylla Sepsis Assay Product Overview
  • Idylla Syndromic Immunocompromised Panel
  • Idylla Syndromic Immunocompromised Panel Product Overview
  • Idylla Syndromic Panel - Tropical Fever
  • Idylla Syndromic Panel - Tropical Fever Product Overview
  • Idylla System - Multiplex Companion Diagnostics Test
  • Idylla System - Multiplex Companion Diagnostics Test Product Overview
  • Idylla Test - Cell Therapy Monitoring
  • Idylla Test - Cell Therapy Monitoring Product Overview
  • Idylla Viral Load Assay - HBV
  • Idylla Viral Load Assay - HBV Product Overview
  • Idylla Viral Load Assay - HCV
  • Idylla Viral Load Assay - HCV Product Overview
  • Idylla Viral Load Assay - HIV
  • Idylla Viral Load Assay - HIV Product Overview
  • Idylla-ctBRAF Test - Melanoma
  • Idylla-ctBRAF Test - Melanoma Product Overview
  • SeptiCyte Triage
  • SeptiCyte Triage Product Overview
Biocartis Group NV - Key Competitors

Biocartis Group NV - Key Employees

Biocartis Group NV - Locations and Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • Biocartis Group NV, Recent Developments
  • Mar 05, 2020: Biocartis Group: Biocartis announces 2019 results and 2020 outlook
  • Mar 05, 2020: Biocartis announces new immuno-oncology project with Bristol-Myers Squibb aimed at registration of Idylla MSI test in China
  • Jan 27, 2020: Biocartis announces resignation CFO
  • Jan 09, 2020: Biocartis meets 2019 key business objectives
  • Nov 14, 2019: Biocartisb Q3 2019 business update
  • Nov 14, 2019: Biocartis Q3 2019 business update
  • Oct 28, 2019: Biocartis launches liquid biopsy testing Idylla ctEGFR Mutation Assay
  • Sep 23, 2019: Five Idylla Performance Studies to be Presented at ‘European Society for Medical Oncology’ congress
  • Sep 05, 2019: Biocartis announces H1 2019 results
  • Aug 05, 2019: Study on performance data of Idylla NRAS-BRAF Mutation Assay at 71st AACC Annual Scientific Meeting in Anaheim, CA (US)
Appendix
  • Methodology
  • About the Publisher
  • Contact Us
  • Disclaimer
List of Tables
  • Biocartis Group NV Pipeline Products and Ongoing Clinical Trials Overview
  • Biocartis Group NV Pipeline Products by Equipment Type
  • Biocartis Group NV Pipeline Products by Indication
  • Biocartis Group NV, Key Facts
  • Biocartis Group NV, Major Products and Services
  • Biocartis Group NV Number of Pipeline Products by Development Stage
  • Biocartis Group NV Pipeline Products Summary by Development Stage
  • EGFR Colon Cancer Test - Product Status
  • EGFR Colon Cancer Test - Product Description
  • Idylla - EGFR/BRAF+ Test - Product Status
  • Idylla - EGFR/BRAF+ Test - Product Description
  • Idylla - KRAS-NRAS-BRAF Test - Product Status
  • Idylla - KRAS-NRAS-BRAF Test - Product Description
  • Idylla ABC Assay - Product Status
  • Idylla ABC Assay - Product Description
  • Idylla Blood Stream Infections Panel - Product Status
  • Idylla Blood Stream Infections Panel - Product Description
  • Idylla Companion Diagnostic Assay - Product Status
  • Idylla Companion Diagnostic Assay - Product Description
  • Idylla ctEGFR Assay - Product Status
  • Idylla ctEGFR Assay - Product Description
  • Idylla Endometrium Assay - Product Status
  • Idylla Endometrium Assay - Product Description
  • Idylla Endpoint CDx Test - Product Status
  • Idylla Endpoint CDx Test - Product Description
  • Idylla Extended KRAS Mutation Test - Product Status
  • Idylla Extended KRAS Mutation Test - Product Description
  • Idylla Extended NRAS Mutation Test - Product Status
  • Idylla Extended NRAS Mutation Test - Product Description
  • Idylla Gene Fusion Assay - Product Status
  • Idylla Gene Fusion Assay - Product Description
  • Idylla Hematology Assay - Product Status
  • Idylla Hematology Assay - Product Description
  • Idylla HPV Test - Head & Neck Cancer - Product Status
  • Idylla HPV Test - Head & Neck Cancer - Product Description
  • Idylla Immuno Tx Panel Test - Product Status
  • Idylla Immuno Tx Panel Test - Product Description
  • Idylla KRAS Mutation Test - Product Status
  • Idylla KRAS Mutation Test - Product Description
  • Idylla Meningitis Assay - Product Status
  • Idylla Meningitis Assay - Product Description
  • Idylla MERS Assay - Product Status
  • Idylla MERS Assay - Product Description
  • Idylla MSI CDx - Product Status
  • Idylla MSI CDx - Product Description
  • Idylla MSI Test - Product Status
  • Idylla MSI Test - Product Description
  • Idylla Multiplex Respiratory Panel - Product Status
  • Idylla Multiplex Respiratory Panel - Product Description
  • Idylla Neuro Panel Test - Product Status
  • Idylla Neuro Panel Test - Product Description
  • Idylla Neurological Disease Assay - Product Status
  • Idylla Neurological Disease Assay - Product Description
  • Idylla NGS Prep Panel - Lung - Product Status
  • Idylla NGS Prep Panel - Lung - Product Description
  • Idylla NRAS Mutation Test - Product Status
  • Idylla NRAS Mutation Test - Product Description
  • Idylla NRAS-BRAF Mutation Test - Product Status
  • Idylla NRAS-BRAF Mutation Test - Product Description
  • Idylla Oncotype DX Prostate - Product Status
  • Idylla Oncotype DX Prostate - Product Description
  • Idylla Resistance Monitoring Assay - Product Status
  • Idylla Resistance Monitoring Assay - Product Description
  • Idylla Retrieve - NGS Hotspot Panel Assay - Product Status
  • Idylla Retrieve - NGS Hotspot Panel Assay - Product Description
  • Idylla Sepsis Assay - Product Status
  • Idylla Sepsis Assay - Product Description
  • Idylla Syndromic Immunocompromised Panel - Product Status
  • Idylla Syndromic Immunocompromised Panel - Product Description
  • Idylla Syndromic Panel - Tropical Fever - Product Status
  • Idylla Syndromic Panel - Tropical Fever - Product Description
  • Idylla System - Multiplex Companion Diagnostics Test - Product Status
  • Idylla System - Multiplex Companion Diagnostics Test - Product Description
  • Idylla Test - Cell Therapy Monitoring - Product Status
  • Idylla Test - Cell Therapy Monitoring - Product Description
  • Idylla Viral Load Assay - HBV - Product Status
  • Idylla Viral Load Assay - HBV - Product Description
  • Idylla Viral Load Assay - HCV - Product Status
  • Idylla Viral Load Assay - HCV - Product Description
  • Idylla Viral Load Assay - HIV - Product Status
  • Idylla Viral Load Assay - HIV - Product Description
  • Idylla-ctBRAF Test - Melanoma - Product Status
  • Idylla-ctBRAF Test - Melanoma - Product Description
  • SeptiCyte Triage - Product Status
  • SeptiCyte Triage - Product Description
  • Biocartis Group NV, Key Employees
  • Biocartis Group NV, Subsidiaries
  • Glossary
List of Figures
  • Biocartis Group NV Pipeline Products by Equipment Type
  • Biocartis Group NV Pipeline Products by Development Stage
Note: Product cover images may vary from those shown
  • Biotechnostics GmbH
  • Roche Diagnostics International Ltd
  • Buhlmann Laboratories AG
  • Celyad Oncology
  • Augurix SA
Note: Product cover images may vary from those shown
Adroll
adroll